Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01990443 · ClinicalTrials.gov registry record · Phase 1
Absolute Bioavailability of Reslizumab in Healthy Subjects
A Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT01990443 is a Phase 1 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 75 participants.
The verdict
NCT01990443, a Phase 1 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the absolute bioavailability of reslizumab following administration of a single subcutaneous (sc) dose to healthy non-Japanese participants
Interventions
- DRUG Reslizumab IV
- DRUG Reslizumab SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01990443
The ClinicalTrials.gov registry entry for NCT01990443 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Reslizumab IV is the first listed.
NCT01990443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01990443 about?
NCT01990443 is a clinical study titled "Absolute Bioavailability of Reslizumab in Healthy Subjects". The primary objective of this study is to assess the absolute bioavailability of reslizumab following administration of a single subcutaneous (sc) dose to healthy non-Japanese participants
What is the current status of trial NCT01990443?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2013-06. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01990443?
The interventions under investigation include: Reslizumab IV (DRUG), Reslizumab SC (DRUG).
Who is sponsoring clinical trial NCT01990443?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.